Home Tags Trastuzumab deruxtecan

Tag: Trastuzumab deruxtecan

US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC

The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...

Following Positive Results of Phase III TULIP Trial: FDA Accepts Byondis’...

The U.S. Food & Drug Administration (FDA) has accepted Byondis' submission of a Biologics License Application (BLA) for trastuzumab duocarmazine (previously known as...

Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...

The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...
Daiichi Sankyo

FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...

The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
ESMO 2017 - 3

Trastuzumab Deruxtecan Receives Breakthrough Therapy Designation for HER2+ Metastatic Breast Cancer...

The U.S. Food and Drug Administration (FDA) has granted trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca), a HER2 directed antibody-drug conjugate (ADC), Breakthrough Therapy...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Remegen’s Disitamab Vedotin Attracts China’s largest-ever out-license Agreement at US $...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

First patient Dosed with Trastuzumab Deruxtecan in DESTINY-Breast09 Head-to-Head HER2+ mBC...

A first patient was dosed in DESTINY-Breast09 (NCT04784715), a global head-to-head Phase 3 clinical trial evaluating the safety and efficacy of trastuzumab deruxtecan (Enhertu®;...

Daiichi Sankyo Reaffirms Long-term Goals with Increased Investment in ADCs

With the launch of fam-trastuzumab-deruxtecan-nxki (Enhertu®), Daiichi Sankyo's first antibody-drug conjugates, coupled with a strong pipeline of innovative ADC, the company has established a...

José Baselga, a Leading Cancer Researcher, Dies at 61

José Baselga, MD, Ph.D., an internationally renowned expert in the development of molecular targeted agents, the R&D chief at AstraZeneca, who had earlier been...

The Story of World ADC Digital

As we plan ahead, for the upcoming digital World ADC Europe with much greater confidence, we were reflecting on what a year it has...

X